Sirona Biochem Corp. and Bloom Burton & Co. have signed a joint venture to research, develop, and commercialize new therapeutics in the areas of inflammation and infectious disease.
The companies will work to identify and design numerous anti-inflammatory and anti-infective compounds. Sirona will be responsible for the chemistry using its expertise in fluorination technology. Bloom Burton will be responsible for financing, clinical validation and commercialization of the compounds.
"We are extremely excited to be working alongside Bloom Burton, a national leader in healthcare-specialized investment banking," said Neil Belenkie, chief executive officer of Sirona Biochem. "This joint venture will combine the best of our expertise to develop the compounds, expanding our product portfolio and delivering innovative solutions in therapeutic areas with unmet needs."
"We have always appreciated the strength of Sirona's chemistry platform and we are excited to explore opportunities in two important and unmet therapeutic indications," said Brian Bloom, president of Bloom Burton & Co. "In addition to capital raising, advisory, equity research and direct investments, Bloom Burton is excited to expand its activities to include company creation and incubation, which should create value for Sirona shareholders and our firm."